Lin Guo-Zhen, Yang Ju-Tian, Wei Suo-Cheng, Chen Shi-En, Huo Sheng-Dong, Ma Zhong-Ren
The Key Bio-Engineering and Technology Laboratory of National Nationality Commission, Northwest University for Nationalities, Lanzhou, 730030, China.
College of Life Science and Engineering, Northwest University for Nationalities, Lanzhou, 730030, China.
Trop Anim Health Prod. 2018 Jun;50(5):957-963. doi: 10.1007/s11250-018-1517-7. Epub 2018 Feb 28.
Brucella poses a great threat to animal and human health. Vaccination is the most promising strategy in the effort to control Brucella abortus (B. abortus) infection, but the currently used live vaccines interfere with diagnostic tests and could potentially result in disease outbreak. Therefore, new subunit vaccines and combined immunization strategies are currently under investigation. In this study, immunogenicity and protection ability of a recombinant adenovirus and plasmid DNA vaccine co-expressing P39 and lumazine synthase proteins of B. abortus were evaluated based on the construction of the two molecular vaccines. Four immunization strategies (single adenovirus, single DNA, adenovirus/DNA, DNA/adenovirus) were investigated. The results showed that the immunization strategy of DNA priming followed by adenovirus boosting induced robust humoral and cellular immune responses, and it significantly reduced the numbers of B. abortus in a mouse model. These results suggest that it could be a potential antigen candidate for development of a new subunit vaccine against B. abortus infection.
布鲁氏菌对动物和人类健康构成巨大威胁。疫苗接种是控制流产布鲁氏菌（B. abortus）感染最具前景的策略，但目前使用的活疫苗会干扰诊断测试，并可能导致疾病爆发。因此，新型亚单位疫苗和联合免疫策略目前正在研究中。在本研究中，基于两种分子疫苗的构建，评估了共表达流产布鲁氏菌P39和核黄素合酶蛋白的重组腺病毒和质粒DNA疫苗的免疫原性和保护能力。研究了四种免疫策略（单一腺病毒、单一DNA、腺病毒/DNA、DNA/腺病毒）。结果表明，DNA初免后腺病毒加强的免疫策略诱导了强烈的体液和细胞免疫反应，并显著减少了小鼠模型中流产布鲁氏菌的数量。这些结果表明，它可能是开发抗流产布鲁氏菌感染新型亚单位疫苗的潜在抗原候选物。
